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Abstract
Microcalcifications are important diagnostic indicators of disease in breast tissue. Tissue microenvironments differ in many
aspects between normal and cancerous cells, notably extracellular pH and glycolytic respiration. Hydroxyapatite
microcalcification microstructure is also found to differ between tissue pathologies, including differential ion substitutions and
the presence of additional crystallographic phases. Distinguishing between tissue pathologies at an early stage is essential to
improve patient experience and diagnostic accuracy, leading to better disease outcome. This study explores the hypothesis that
microenvironment features may become immortalised within calcification crystallite characteristics thus becoming indicators of
tissue pathology. In total, 55 breast calcifications incorporating 3 tissue pathologies (benign – B2, ductal carcinoma in-situ - B5a
and invasive malignancy - B5b) from archive formalin-fixed paraffin-embedded core needle breast biopsies were analysed using
X-ray diffraction. Crystallite size and strain were determined from 548 diffractograms usingWilliamson-Hall analysis. There was
an increased crystallinity of hydroxyapatite with tissue malignancy compared to benign tissue. Coherence length was signifi-
cantly correlated with pathology grade in all basis crystallographic directions (P < 0.01), with a greater difference between benign
and in situ disease compared to in-situ disease and invasive malignancy. Crystallite size and non-uniform strain contributed to
peak broadening in all three pathologies. Furthermore, crystallite size and non-uniform strain normal to the basal planes increased
significantly with malignancy (P < 0.05). Our findings support the view that tissue microenvironments can influence differing
formation mechanisms of hydroxyapatite through acidic precursors, leading to differential substitution of carbonate into the
hydroxide and phosphate sites, causing significant changes in crystallite size and non-uniform strain.
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Introduction
Breast cancer is the most commonly diagnosed cancer in
women in the UK [1]. Screening mammography potentially
identifies cases at an early stage by analysing features, includ-
ing the presence of masses, asymmetric soft tissue densities
andmicrocalcifications [2, 3].Microcalcifications are deposits
of calcium salts with diameters not exceeding 1 mm [4].
Mammographic interpretation is based on distribution, size
and morphology and may result in patients being recalled
for further investigation through core needle biopsy.
However, only 21% of women recalled for biopsy receive a
subsequent diagnosis of cancer, meaning that the positive pre-
dictive value of mammography needs to be improved upon
[2]. Studies have shown malignant calcifications identified
through mammography are mostly related to pure DCIS
(64%) or DCIS with invasive foci (32%) but rarely with pure
invasive carcinoma (4%) [5]. Therefore, mammographically
identified calcifications are predominantly used for discrimi-
nating cases of DCIS from benign, and between DCIS grades.
The calcification based on chemical composition may be
broadly split into two categories; type I are amber, partially
translucent and birefringent, whereas type II, are grey-white
and opaque [6]. Type I calcifications consist of calcium oxa-
late dihydrate (CaC2O4.2(H2O)) and are predominantly found
associated with benign conditions, whereas type II calcifica-
tions are composed primarily of calcium phosphate in the
form of hydroxyapatite (Ca10(PO4)6(OH)2) and are associated
with benign, in-situ and cancerous breast tissues [6]. These
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apatite calcifications consist of crystallites with nanometre
dimensions.
To date, numerous in vivo formation mechanisms for hy-
droxyapatite (HAp) calcification have been postulated.
Evidence of osteoblast-like cells has been observed in breast
cancer, which may implicate a bone-like deposition mecha-
nism in cancer cells [7]. There is also evidence for an imbal-
ance of mineralisation promoters and inhibitors in breast can-
cer, such as alkaline phosphatase which may cause calcifica-
tion [8, 9]. This mechanism may be linked to a secretory
process where secreted vesicles are calcified in the extracellu-
lar matrix [10]. Additionally, necrosis is a common feature of
high-grade DCIS, which may act as a nucleation centre for
calcifications [10]. While there is evidence to support these
mechanisms, the actual process of HAp formation from pre-
cursors in breast tissue is relatively unexplored. The mecha-
nism of HAp deposition can occur through a number of pre-
cursors such as amorphous calcium phosphate (ACP)
(Ca9(PO4)6), and often other intermediate phases [11]. Such
precursor phases are dependent on factors such as environ-
mental pH and temperature, which can affect the kinetics of
ACP to HAp transformation, as well as the progression
through other intermediate phases. For example, at low pH,
acidic precursors such as octacalcium phosphate (OCP)
(Ca8(HPO4)2(PO4)6·5H2O) and dicalcium phosphate
dihydrate (DCPD) are more likely to form prior to HAp for-
mation, whereas at neutral or alkaline pH, evidence suggests
the more direct conversion of ACP to HAp [11].
Cancerous tissues are known to have a wide array of dif-
ferences to normal and benign tissues in terms of their micro-
environments, with some of these differences also evident
between ductal carcinoma in-situ (DCIS – herein referred to
as ‘in-situ’) and invasive cancer cells. This includes gene and
protein expression, such as oestrogen and progesterone recep-
tor positivity; inflammation; immune cells recruitment such as
leukocytes and ion trafficking [12, 13]. Some factors affecting
the formation mechanisms of HAp also differ between the
microenvironments of cancerous and normal breast tissues.
For example, the extracellular pH of invasive cancer cells is
more acidic than benign and in-situ cells, hence an increased
cell invasiveness [12]. It is the combination of these changes
that permits the initial carcinogenesis and the progression
from in-situ to invasive and metastatic cancers by maintaining
feedback loops, enabling angiogenesis and facilitating cellular
migration [13]. While histopathology of biopsies can analyse
some of these characteristic features, how these environments
i n f l u e n c e mammog r a p h i c f i n d i n g s i n c l u d i n g
microcalcifications has not previously been explored.
Phy s i c o ch em i c a l d i f f e r e n c e s b e twe en HAp
microcalcifications associated with benign proliferative con-
ditions, in-situ carcinoma and invasive cancers have been ob-
served by previous studies [14, 15]. For example, sodium
incorporation in the HAp has been reported to increase with
tissue malignancy [15]. Further, the amount of β-tricalcium
phosphate (whitlockite) as the magnesium substituted phase
within type II calcifications has been shown to quantitatively
increase with increasingly malignant tissue [15]. The struc-
tures of HAp, OCP and whitlockite are shown in Fig. 1.
HAp is an enigmatic material, that can accommodate mul-
tiple substitutional ions, which affects the crystallographic
properties determined using X-ray diffraction (XRD) tech-
niques [16–18]. Therefore, XRD is a useful tool in determin-
ing fine structural differences in type II breast calcifications.
XRD is used to investigate multiple properties, including
‘crystallinity’, ‘coherence length’, ‘lattice parameters’, crys-
tallite size and non-uniform strain. Here, crystallinity refers
to the degree of order found within the crystal structure, with
the less crystalline materials exhibiting greater diffraction
peak broadening [18]. Coherence length is the average (direc-
tion dependent) distance within a crystal that lattice order per-
sists. Decreasing coherence length increases the magnitude of
peak broadening therefore can be used as a quantitative mea-
sure of crystallinity [19]. Lattice disorder arises from a number
of phenomena and coherence length is therefore often sepa-
rated into crystallite size, (the average physical dimension
individual crystallites in a given direction), and non-uniform,
or inhomogeneous, strain (intra-crystallite imperfections)
[19]. Finally, lattice parameters define the shape and lengths
of the individual, molecular repeating units (unit cells) that
make up the crystallite structure. These are denoted as ‘a’
and ‘c’ for HAp [18].
Numerous substitutions into the HAp lattice have been
observed. For example, halide ions can substitute for hydrox-
ide, hydrogen phosphate substitutes into the phosphate site
and sodium and magnesium can substitute for calcium [16].
Perhapsmost significantly, carbonate ions have been shown to
substitute into the HAp lattice in two distinct sites: at the
hydroxyl site (A-type); and the phosphate site (B-type).
Additionally, carbonate can adsorb onto the surface of HAp
crystals, where it is labile and does not form part of the lattice
[18]. In synthetic preparations of hydroxyapatite, the type of
carbonate substitution has been shown to be affected by the
carbonate concentration in the surrounding environment, with
higher carbonate concentrations, up to 4 wt%, favouring A-
type carbonate and lower carbonate concentrations favouring
B-type carbonate, though the opposite trend is observed be-
yond 4 wt% [20]. Carbonate substitution is also known to
have several effects on the properties of HAp, for example,
increasing carbonate substitution has been shown to increase
HAp solubility [21].
It is generally accepted that all biological apatites contain
carbonate substitution to some extent, varying from 2 to 6%
weight in enamel, dentine and bone, and is thought to be
dominated by B-type substitution, with A/B type ratio ranging
from 0.7–0.9 [18, 22–24]. In synthetic apatites, increasing
total levels of carbonate substitution have been correlated with
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decreasing crystallite size, and increasing non-uniform strain
[17, 21, 25]. Previous studies have also demonstrated a de-
crease in total carbonate concentration in calcifications with
increasing tissue malignancy, from benign to invasive, in the
range of 1–2 wt% [22, 26]. Together, an increase in crystallite
size and decrease in non-uniform strain with increasing tissue
malignancy would be expected. However, there is limited ev-
idence to indicate how carbonate is distributed between sites,
although each may have differing effects on the physicochem-
ical properties of HAp [22, 27]. For example, A- and B-type
carbonate substitution have complementary effects on the
crystallographic ‘a’ and ‘c’ lattice parameters [28]. Previous
work has also reported an association of larger crystal coher-
ence length with increasing malignancy [14].
As crystallites precipitate, features of the local tissue chem-
istry may become ‘immortalised’ within the individual crys-
tals that subsequently remain stable until such time as resorp-
tion occurs. Thus, identifying differences in the microstructure
of HAp calcifications in breast tissue may provide insights
into relat ionships between tissue pathology and
microcalcification structure. Detailed characterisation of cal-
cification microstructure therefore has the potential for
diagnostic utility, particularly when distinguishing between
the range of breast pathologies observed. This preliminary
study aims to further investigate the differences in HAp crys-
tals found in benign and pathological breast tissue by
analysing crystallite size and non-uniform strain using X-ray
crystallographic analysis.
Materials and Methods
Tissue Specimens
Formalin-fixed, paraffin-embedded (FFPE) core biopsy breast
specimens from the Gloucestershire Hospitals NHS
Foundation Trust diagnostic archive from 2012 (under ap-
proval from the Gloucestershire Local Research Ethics
Committee) were randomly selected subject to the presence
of calcifications in the histopathology report, and a classifica-
tion of ‘B2—Benign’, ‘B5a—Ductal Carcinoma In Situ’, or
‘B5b—Invasive Carcinoma’ [14]. Blocks were provided with
a histopathology report further detailing any associated necro-
sis and microanatomic location and subsequently scanned
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Fig. 1 The structure of single repeating units (unit cells) of breast microcalcification phases. a a unit cell of hydroxyapatite (HAp), b a unit cell of
octacalcium phosphate (OCP), c a unit cell of magnesium whitlockite. Arrows indicate the three directions of the lattice parameters ‘a’, ‘b’ and ‘c’
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using a Nikon Metrology XT H225 CT system at 20 kV to
select for significant levels of calcification. Where samples
were classified as Benign, the histopathology reports fibrocys-
tic changes, and in some cases, hyperplasia or fibroadenoma,
with no evidence of malignancy. Calcification was associated
with fibroadenoma or sclerotic stroma. Where samples were
classified as Ductal Carcinoma in Situ, they exhibit interme-
diate or high grade DCIS pathology, there was evidence of
comedo necrosis in 2/4 of samples and there was no evidence
of invasive malignancy within the biopsies. Calcifications
were located inside the breast duct and associated with com-
edo necrosis, where present.Where samples were classified as
Invasive Carcinoma, there was associated DCIS in 4/6 cases,
and only calcifications associated with the invasive compo-
nent were measured.
Crystallographic Analysis
5 μm sections were cut from each block and mounted on
12.5 μm thick polyolefin heat shrink films stretched over
38 mm diameter aluminium alloy rings and held in place with
rubber ‘O’ rings. Geometric calibrations of the instrumenta-
tion were undertaken using a National Institute of Standards &
Technology, Standard Reference Material 640c silicon pow-
der. This was made into slurry in a dilute solution of PVA
adhesive and painted onto the mounting films in the plane of
the tissue sections [14].
Data collections were carried out at the Diamond Light
Source, Didcot, UK on beamline i18. The sample rings were
clamped perpendicular to the X-ray beam on a motorized
stage and measurements made in transmission using a beam
spot size of 10 × 10 μm, and an energy of 10.0 keV. Data was
collected from 11 equally spaced positions in a vertical line
across each calcification with an exposure time of 30 s per
point. In total, 548 diffractograms were collected from 55
separate calcifications in 15 specimens, consisting of 5 be-
nign, 4 in-situ, and 6 invasive (16, 17 and 22 calcifications
respectively).
Data Analysis
The 1-D data produced (“diffractograms”), exhibited a large
background to signal ratio, and therefore the background was
subtracted using Eva (BRUXER AXS) before microstructural
analysis in TOPAS 4.2 software (BRUXER AXS).
Crystallographic phase identification was carried out using
the International Centre for Diffraction Data (ICDD) database
(PDF-4, 2018).
A valuable feature of X-ray diffraction as an analytical
approach is that CL may be determined for different crystal-
lographic directions and thus provides access to several inde-
pendent potential biomarkers [29, 30]. Each unique diffraction
peak represents scattering from crystallographic planes in
specific orientations and thus, by appropriate choice of
Bragg maxima, the CL may be considered in three directions,
<00ℓ>, <hk0> and < 0 k0>.
For each diffractogram, the HAp coherence length (CL)
was calculated from the fitted full-width half-maximum (β)
of the (002), (004), (030) and (210) diffraction maxima, using
the Scherrer equation [30]:
CL ¼ Kλ
βcos θ
ð1Þ
where K is the Scherrer constant (0.9), λ is the X-ray wave-
length (0.124 nm) and θ is the Bragg angle.
The anisotropy of hydroxyapatite crystals means size and
non-uniform strain must be separated for each crystallograph-
ic direction. Profile fitting of hk0 and 0 k0 peaks other than
(210) and (030) are unreliable due to overlapping and there-
fore accurate separation of crystallite size and strain is not
possible for the associated directions. Therefore, the CL was
segregated into crystallite size and non-uniform strain calcu-
lated for the <00ℓ> direction from the (002) and (004) maxima
using the Williamson-Hall method [31]:
βcosθ ¼ 4εsinθþ Kλ
L
ð2Þ
where β is the FWHM,, L is the crystallite size,, and ε is the
non-uniform strain.
Parameterised data (coherence length, crystallite size and
non-uniform strain) was averaged per calcification before car-
rying out statistical analyses. Data was tested for normality
using the Anderson-Darling test at a 95% confidence level.
Where data did not possess a normal distribution, statistical
analysis between groups was carried out using the Mann-
Whitney U test at a 95% confidence level in Minitab 17
Statistical Software.
Relative values of coherence length, crystallite size and
non-uniform strain are compared below.
Results
The averaged diffractograms of benign, in-situ and invasive
calcifications and a stochiometric, highly crystalline HAp are
shown in Fig. 2. Tissue calcifications in all three conditions
were identified uniquely as HAp. Comparing diffractograms
from the biogenic HAp to that of the stoichiometric sample, it
is clear that the diffraction peaks are broadened in all three
biogenic cases, indicating that none of these samples consist
of structurally ordered HAp. This is typical of biogenic apa-
tites such as bone mineral. Overall peak broadening (related to
coherence length, see Eq. 1) decreased from benign to in-situ
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to invasive calcifications. This is particularly apparent in the
overlapping group of 211, 112, 030 and 202 maxima which
become progressively better defined with increasing
malignancy.
There was a significant increase in CL between benign and
in-situ calcifications in <00ℓ> (p < 0.01) and < 0 k0>
(p < 0.01) directions, and between in-situ and invasive for
the <0 k0> direction (p < 0.01), as shown in Fig. 3. The rela-
tive difference between benign and in-situ calcifications for
the <00ℓ>, <hk0> and < 0 k0> directions are similar (25%,
22% and 27%), while the difference between in-situ and in-
vasive is smaller than the difference between benign and in-
situ in all three cases. However, the percentage difference
between in-situ and invasive calcifications is more pro-
nounced in the <0 k0> and < hk0> directions (23% and
19%) compared to the <00ℓ> (11%) direction.
A significant increase in crystallite size with increasing
malignancy (p < 0.05, Fig. 4a) was demonstrated. The crystal-
lite size (in the <00ℓ> direction) increased by 40% from be-
nign to in-situ tissues (p < 0.01), whereas an increase of 21%
was observed from in-situ to invasive (p < 0.05). Non-uniform
strain was also found to significantly increase with malignan-
cy. Statistically significant differences were observed between
benign and invasive (p < 0.05) and in-situ and invasive
(p < 0.05) calcifications (Fig. 4b). In contrast to differences
in coherence length and crystallite size, there was a greater
increase from in-situ to invasive calcification non-uniform
strain (42%) compared to benign to in-situ (7%).
Discussion
In summary, our findings demonstrate significant increases in
coherence length, crystallite size and non-uniform strain of
calcifications with increasing tissue malignancy. Values of
these characteristics were comparable to other natural apatites;
with size ranging from 23 to 39 nm and non-uniform strain in
the order of 10−3 [21, 25]. These findings support the view that
the mechanisms of calcification formation in different tissue
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Fig. 2 Normalised X-ray
diffractograms of calcifications
associated with benign, in-situ
and invasive breast tissue and
stochiometric HAp. A decrease in
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Fig. 3 Coherence length measurements for benign, in-situ and invasive
calcifications in the 00ℓ, hk0 and 0 k0 directions. Marked points indicate
the average values for each sample. Statistical analysis was carried out
using Mann-Whitney U test, **P < 0.01, ***P < 0.001. Error bars repre-
sent 95% confidence intervals
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microenvironments may vary, thus below we propose a new
model for this process. This is summarised in Fig. 5.
Tissue Microenvironment and Calcification Formation
Tissue microenvironments surrounding benign, in-situ and in-
vasive cells can differ greatly and therefore the ionic milieu
within which calcifications form is varied. The ability of an
invasive cell to metastasise is governed by the conditions in its
microenvironment, which is moderated by numerous factors
including pH, proteins, the extracellular matrix, cellular
processes and ion concentrations [12]. Biogenic calcifications
are also known to possess different characteristics, such as
phase composition and carbonate content when associated
with different tissue pathologies [14, 15, 22].
Acidity is an important factor for calcification formation.
Extracellular acidity is also a key marker for cancer aggres-
siveness, caused by the switch to a glycolytic respiration type,
induced by hypoxia in tumour cells, known as the Warburg
effect. Glycolysis produces a higher level of hydrogen ions
compared to aerobic respiration, which in turn efflux from the
cytoplasm to maintain a neutral or alkaline intracellular pH,
High carbonate HypoxiaNormal respiration
Neutral extracellular
pH
ACP precursor
A & B-type carbonate
Benign cells Cancer cells
B-type carbonate
Acidic extracellular
pH
OCP precursor
DCIS
Increasing malignancy
Less strain More strain
Low carbonate
Smaller crystallites Larger crystallites
Fig. 5 Summary diagram showing the microenvironmental factors affecting the incorporation of different types of carbonate into HAp in
microcalcifications associated with benign, DCIS and invasive breast tissue cells
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causing the extracellular pH to become more acidic [12, 32,
33]. In addition, the action of carbonic anhydrases (CA), in-
tracellularly and extracellularly, leads to an acidic extracellular
pH due to the conversion of water carbon dioxide to hydrogen
and bicarbonate ions in the extracellular fluid [34]. The ex-
pression of one extracellularly acting CA, CAIX, has also
been associated with higher DCIS grade and invasive carci-
noma, concurrent with an increasingly acidic extracellular pH
with malignancy [35, 36].
An impact on calcification formation is reported in
studies where an acidic pH increases the likelihood of
forming an acidic precursor during the hydroxyapatite for-
mation process [11]. Neutral and alkaline pH favours the
direct conversion from ACP to HAp, whereas an acidic
pH causes the formation of an additional precursor such
as OCP [37]. Therefore, differences in extracellular pH
between benign, in-situ and invasive cells would result
in different formation mechanisms for hydroxyapatite
microcalcifications. These different formation mecha-
nisms lead to the incorporation of different types of car-
bonate substitution; ACP hydrolysis favouring substitu-
tion of carbonate into both the hydroxide site (A-type)
and phosphate site (B-type) whereas OCP hydrolysis fa-
vours the incorporation of carbonate within the B-type
sites [38]. Therefore, benign cell, neutral pH environ-
ments promote ACP hydrolysis that is more likely to pro-
duce A/B carbonated apatites, whereas invasive cell envi-
ronments, (favouring OCP hydrolysis), would result in
predominantly B-type carbonate apatites. This is further
supported by the observations that sodium incorporation
into the HAp lattice induces OCP formation, and sodium
substitution is highest in invasive calcifications [15, 39].
Hypoxia has also been shown to initiate osteogenic dif-
ferentiation in other cell types, therefore may contribute to
the differing formation mechanisms between benign, in-
situ and invasive breast tissue pathologies [40].
Additionally, at low carbonate weight percentages
(<4 wt%), a lower carbonate wt% has been associated with
B-type carbonate substitution, and a higher wt% favours A-
type [20]. Taken together with studies reporting a lower total
carbonate level in invasive calcifications and increasing levels
with decreasing malignancy, this suggests the favouring of B-
type carbonate in invasive calcifications, and A-type in benign
[22].
Together the acidic extracellular pH and previously report-
ed carbonate concentrations in microcalcifications suggests a
higher level of B-type carbonate in HAp calcifications associ-
ated with invasive tissue pathology. Equally, the neutral pH
and higher carbonate wt%of benign cells suggest an increased
A-type carbonate incorporation. These mechanisms are
reflected in the microstructure measurements and lattice pa-
rameters measured in benign, in-situ and invasive
calcifications.
Calcification Microstructure
Previous studies have demonstrated a decrease in total carbon-
ate substitution with increasing tissue malignancy, which
should lead to an increase in crystallite size with malignancy
[17, 22]. This observation is also supported by our data;
microcalcifications associated with invading tumours were
characterised to possess the largest crystallite size (Fig. 4)
For the first time, our analysis also enables a more specific
inference regarding the lattice carbonate distribution.
Increasing total carbonate substitution has also been linked
to an increase in non-uniform strain, therefore a decrease in
non-uniform strain with malignancy would be expected [21].
However, the data presented here indicates the opposite trend.
B-type substitutions have previously been shown to increase
non-uniform strain [17]. B-type substitutions will, in princi-
ple, for the same number of substitutions, produce greater
non-uniform strain than that of A-type. This is because car-
bonate substitution for phosphate occurs randomly at 6 crys-
tallographically equivalent sites (hm) within the unit cell,
compared to 2 (e3) for hydroxide substitutions. The non-
uniform strain values observed within this study, suggests an
increasing B-type carbonate substitution with increasing ma-
lignancy. However, given the total carbonate decreases with
malignancy, this study suggests that lattice carbonate of breast
microcalcifications occupies both A-type and B-type sites
[22].
This model is further supported by previous estimates of
apatite unit cell dimensions as revealed by lattice parameter
measurements. A-type carbonate substitutions increase the ap-
atite ‘a’ axis due to CO3 having a significantly greater ionic
radius than OH. In contrast, B-type carbonate decreases the ‘a’
axis due to CO3 having a smaller radius than phosphate [28].
In addition, A-type carbonate substitutions decreases the ‘c’
axis and B-type increases the ‘c’ axis [28]. Previous studies
have shown a decrease in the ‘a’ axis with malignancy and an
increase in the ‘c’ axis, further supporting the view that the
quantity of B-type carbonate substitution increases and A-type
substitution decreases with increasing malignancy [14].
The distribution of data observed in all the Williamson-
Hall plots is indicative of microstructural anisotropy. The lack
of reliable peaks in reflections other than the 00ℓ means that
only data in this reflection could be separated into size and
non-uniform strain. However, the noted increases in CL with
malignancy in all three reflections analysed (Fig. 3) suggest
that crystallite size and/or non-uniform strain are also chang-
ing in the <hk0> and < 0 k0> directions. Proteins have been
noted to interact with the non-basal faces of HAp, restricting
growth in neutral pH [41]. Extracellular acidity may cause
changes in protein conformation in cancer cells permitting
increased CL in the <0 k0> and < hk0> directions, hence a
directional variance in difference magnitude. Thus, for the
development of quantitative biomarkers based upon
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microstructural features, appropriate choice of lattice direction
to maximise sensitivity is required.
The Importance of Microstructural Differences
Studies have previously shown that the total carbonate content
of hydroxyapatite is positively correlated with the solubility of
the crystals, which would suggest benign breast calcifications
are more soluble than pathological ones as a consequence of
their respective carbonate contents [21, 22]. However, more
stable calcifications are generally considered to be benign
[42]. A positive correlation between non-uniform strain and
carbonated apatite solubility has previously been found,
which may offer an explanation for this apparent contradic-
tion, where less strained crystallites, i.e. those in benign calci-
fications, are less soluble [21]. This may suggest that the type
of carbonate also has a role to play in other calcification char-
acteristics. In addition, a more acidic pH increases the solubil-
ity of hydroxyapatite, which may also play a role in the rela-
tive instability of calcifications in pathological tissue [43].
Furthermore, the interaction of calcification with proteins
in the surrounding tissue has been shown to play an important
role in the propagation of tumour virulence characteristics. For
example, the presence of hydroxyapatite in mammary cell
lines has been shown to upregulate matrix metalloproteinases
which are key proteins in the degradation of the basement
membrane, enhance mitogenesis, and induce the production
of interleukins (ILs) [44]. It has also been demonstrated that
the surface morphology of hydroxyapatite crystals impacts the
level of protein adsorption on to the crystals, which can have
downstream effects on expression of osteoblastic markers
such as Runt-related transcription factor 2 (RUNX2) and al-
kaline phosphatase (ALP) [45]. Moreover, the substitution of
ions such as carbonate into the hydroxyapatite lattice can af-
fect crystal morphology, meaning that the microstructure of
microcalcifications potentially has the ability to impact down-
stream effectors and hence tumour virulence characteristics
[20, 46].
Conclusions
This paper presents a preliminary set of data that indicates a
role for X-ray diffraction in understanding breast
microcalcification chemistry and formation. The data present-
ed in this paper demonstrates, firstly, that there are measurable
differences in the microstructure of hydroxyapatite calcifica-
tions associated with benign, in-situ and invasive breast tissue
pathologies. Secondly, the data suggests that a combination of
A-type and B-type substituted carbonate is found in breast
microcalcifications, and it is the ratio of these two types that
is specifically related to tissue type. Finally, the differing tissue
microenvironments, caused by differing tissue metabolisms,
combined with the model presented here indicate that the tis-
sue pathology governs the formation mechanisms and there-
fore the composition of calcifications, meaning tissue pathol-
ogy is immortalised within microcalcifications microstructure
in the breast tissue. These differences may have a multitude of
impacts on the propagation of tumour characteristics through
interactions with the microenvironment. We appreciate that
the model proposed is based upon limited observations and
therefore remains somewhat speculative. In addition, it is not
possible to determine whether invasive calcifications are ‘left-
over’ from previous DCIS, but this may be an avenue to ex-
plore in future research. Using an expanded data set, this mod-
el can be developed into a defined algorithm, which may
cement microstructural parameters as a key prognostic indica-
tor for breast disease in the future.
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